Page 107 - Aet News Today

About half of adults, or 45%, said they are at least somewhat interested in taking a “safe, effective weight-loss drug,” according to a new survey by KFF. However, just 16% of adults are still interested in taking weight-loss drugs if they’re not covered by insurance.

Through Scripta Insights’ app, members of its customers can input the medications they’re taking, and the company will provide a savings report that will show different options on how they can save on their prescriptions. Starting in 2024, Cost Plus Drugs may show up as an option in the savings report.

Novo Nordisk weight-loss drug Wegovy reduced the risk of major cardiovascular events by 20% in a large clinical trial. The company said the results support expanding the drug’s label, but the looming question is whether the data will persuade payers to cover the pricey chronic therapy.

Daybreak Health — a startup that partners with school districts to provide children with virtual mental health services — recently closed a $13 million Series B funding round. The company has partnered with more than 60 public school districts since it began providing care in 2019.

Hospitals’ pharmacy spending is projected to rise by 3.42% next year, according to a new report. Specialty drugs, including Ozempic and Humira, as well as neurology medications are the primary drivers of this increase in pharmacy expenses.

Hospitals and outpatient treatment centers in at least three states are struggling to get their systems back online following a ransomware attack waged last week against parent company Prospect Medical Holdings. Some of these facilities have partially or completely halted patient care.

Talkiatry and NOCD are teaming up to improve care for patients with obsessive-compulsive disorder. Talkiatry specializes in medication management, while NOCD specializes in Exposure and Response Prevention therapy.

Izervay, a drug developed by Astellas Pharma subsidiary Iveric Bio, is now the second approved therapy for the degenerative vision-loss disorder geographic atrophy. The regulatory decision comes as safety concerns emerge around the first therapy for the disease, an Apellis Pharmaceuticals product.

Clinical trial design will be one of the topics discussed at the upcoming INVEST Digital Health conference in Dallas on October 26. THREAD Clinical Trial Design Director Noah Goodson highlighted some of the milestones the sector has seen in recent years.

Many Medicaid enrollees are not receiving the information they need from health plans during the return to Medicaid renewals, a new survey shows. Older Medicaid enrollees are especially struggling.